• Vaccine Ontology ID: VO_0004054
• Type: Subunit vaccine
• Status: Research
• Antigen: Purified FbaA protein
• fbaA gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000133
• Immunization Route: subcutaneous injection

• Vaccine Ontology ID: VO_0004055
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant FBP54 protein
• fbp54 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000143
• Immunization Route: Orally

• Vaccine Ontology ID: VO_0004053
• Type: Subunit vaccine
• Status: Research
• Antigen: A polypeptide encompassing a conformational B cell epitope of the M protein conjugated with DT (Schulze et al., 2006).
• emm1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: A polypeptide encompassing a conformational B cell epitope of the M protein (J8, positions 344–355 of the M1 sequence, accession no. X62131) was synthesised, purified and conjugated with DT (Schulze et al., 2006).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001242
  • Description: 10 μg of CTB or 0.5 μg of the TLR2/6 agonist MALP-2 as mucosal adjuvants (Schulze et al., 2006).
• Immunization Route: intranasal immunization

• Vaccine Ontology ID: VO_0004056
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant SfbI protein
• SfbI gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001242
• Immunization Route: intranasal immunization

• Vaccine Ontology ID: VO_0004057
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant Sib35 protein
• sib35 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000139
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunized subcutaneously with purified FbaA + Freund’s adjuvant at weeks 0, 2, and 4 (Ma et al., 2009).
• Challenge Protocol: Mice immunized with FbaA or PBS were injected i.p. with 1 ml bacterial suspension (equivalent to 2 × 10^8 CFU) and monitored
  survival daily for 15 days (Ma et al., 2009).
• Efficacy: 60% of mice immunized with FbpA were protected from challenge with group A streptococcus (Ma et al., 2009).
• Host IgG response
  • Description: Assay for immune response showed that FbaA could induce protein-specific high serum IgG titer in BALB/c mice 10 days after injection. There was no significant difference between the antibody titers of the FbaA vaccine and an M protein vaccine, which is the best immugen of group A streptococcus, and FbaA induced significantly higher titers than PBS-vaccinated mice (Ma et al., 2009).
  • Detailed Gene Information: Click Here.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were orally immunized with cholera toxin (CT; 10 μg)-FBP54 (10 μg) or CT (10 μg)-PBS by using an intubation needle. Immunization was performed four times, on days 0, 14, 28, and 42 (Kawabata et al., 2001).
• Challenge Protocol: Actively immunized mice were intraperitoneally challenged with an appropriate number of CFU of S. pyogenes SSI-1 (M3), SSI-9 (M1), or S42 (M12) on day 51 following immunization (Kawabata et al., 2001).
• Efficacy: Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice (Kawabata et al., 2001).
• Host IgA response
  • Description: An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Nonimmunized control groups did not show any detectable humoral immune responses to FBP54 in sera (Kawabata et al., 2001).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Nonimmunized control groups did not show any detectable humoral immune responses to FBP54 in sera (Kawabata et al., 2001).
  • Detailed Gene Information: Click Here.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunised by intranasal route (10 μl per nostril) with either J8-DT (M protein) (30 μg per dose) co-administered with 10 μg of CTB or 0.5 μg of the TLR2/6 agonist MALP-2 as mucosal adjuvants, on day 0, 7, 14, and 28. Control animals received PBS alone (Schulze et al., 2006).
• Challenge Protocol: Mice were intranasally challenged with 10^8 CFU of the heterologous virulent S. pyogenes strain NS192 in 40 μl of PBS (20 μl per nostril) (Schulze et al., 2006).
• Efficacy: Mice immunized with J8-DT had 60% survival following challenge (Schulze et al., 2006).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: MIce were immunized intranasally with 20 μL of SfbI (H2 fragment) covalently coupled to CTB or with CTB alone as a control on days 1, 3, 5, and 26 (30 mg/dose) (Guzmán et al., 1999).
• Challenge Protocol: On day 36 mice were challenged with 10^6 cfu of S. pyogenes DSM 2071 or NS239, respectively (Guzmán et al., 1999).
• Efficacy: SfbI-vaccinated animals showed 80% and 90% protection against homologous and heterologous challenge (Guzmán et al., 1999).

Mouse Response

• Host Strain: BALB/c, C3H/HeN, C57/BL6 and CD1
• Vaccination Protocol: Six-week-old female mice were separated into two groups, which were either subcutaneously immunized with rSib35 (50 μg) in Freund's complete adjuvant or injected with PBS in FCA on day 0, and given booster injections with rSib35 and Freund's incomplete adjuvant on days 14, 28, and 42 (Okamoto et al., 2005).
• Challenge Protocol: Actively immunized mice were intraperitoneally challenged with an appropriate number of CFUs of strain SSI-1 on day 56 following primary immunization (Okamoto et al., 2005).
• Efficacy: The survival rates of all four-mouse strains were significantly increased by Sib35 vaccination. 100% of the Sib35-immunized C3H/HeN mice survived the potentially lethal GAS challenge, whereas all non-vaccinated C3H/HeN mice died after the challenge (Okamoto et al., 2005).
• Host IgG response
  • Description: Immunization of mice with Sib 35 induced significantly higher antigen-specific IgG antibodies in their sera beginning 28 days after immunization as compared to non immunized control mice (Okamoto et al., 2005).
  • Detailed Gene Information: Click Here.